Active case detection, treatment of falciparum malaria with combined chloroquine and sulphadoxine/pyrimethamine and vivax malaria with chloroquine and molecular markers of anti-malarial resistance in the Republic of Vanuatu by Kinzer, Michael H et al.
RESEARCH Open Access
Active case detection, treatment of falciparum
malaria with combined chloroquine and
sulphadoxine/pyrimethamine and vivax malaria
with chloroquine and molecular markers of anti-
malarial resistance in the Republic of Vanuatu
Michael H Kinzer
1*, Krisin Chand
1, Hasan Basri
1, Edith R Lederman
1, Augustina I Susanti
1, Iqbal Elyazar
1,
George Taleo
2, William O Rogers
1, Michael J Bangs
3, Jason D Maguire
1*
Abstract
Background: Chloroquine-resistant Plasmodium falciparum was first described in the Republic of Vanuatu in the
early 1980s. In 1991, the Vanuatu Ministry of Health instituted new treatment guidelines for uncomplicated
P. falciparum infection consisting of chloroquine/sulphadoxine-pyrimethamine combination therapy. Chloroquine
remains the recommended treatment for Plasmodium vivax.
Methods: In 2005, cross-sectional blood surveys at 45 sites on Malo Island were conducted and 4,060 adults and
children screened for malaria. Of those screened, 203 volunteer study subjects without malaria at the time of
screening were followed for 13 weeks to observe peak seasonal incidence of infection. Another 54 subjects with
malaria were followed over a 28-day period to determine efficacy of anti-malarial therapy; chloroquine alone for
P. vivax and chloroquine/sulphadoxine-pyrimethamine for P. falciparum infections.
Results: The overall prevalence of parasitaemia by mass blood screening was 6%, equally divided between
P. falciparum and P. vivax. Twenty percent and 23% of participants with patent P. vivax and P. falciparum
parasitaemia, respectively, were febrile at the time of screening. In the incidence study cohort, after 2,303 person-
weeks of follow-up, the incidence density of malaria was 1.3 cases per person-year with P. vivax predominating.
Among individuals participating in the clinical trial, the 28-day chloroquine P. vivax cure rate was 100%. The 28-day
chloroquine/sulphadoxine-pyrimethamine P. falciparum cure rate was 97%. The single treatment failure, confirmed
by merozoite surface protein-2 genotyping, was classified as a day 28 late parasitological treatment failure. All
P. falciparum isolates carried the Thr-76 pfcrt mutant allele and the double Asn-108 + Arg-59 dhfr mutant alleles.
Dhps mutant alleles were not detected in the study sample.
Conclusion: Peak seasonal malaria prevalence on Malo Island reached hypoendemic levels during the study
observation period. The only in vivo malaria drug efficacy trial thus far published from the Republic of Vanuatu
showed chloroquine/sulphadoxine-pyrimethamine combination therapy for P. falciparum and chloroquine alone for
P. vivax to be highly efficacious. Although the chloroquine-resistant pfcrt allele was present in all P. falciparum
isolates, mutant alleles in the dhfr and dhps genes do not yet occur to the extent required to confer sulphadoxine-
pyrimethamine resistance in this population.
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Malaria transmission is perennial throughout the Repub-
lic of Vanuatu, but seasonal in intensity. Its epidemiol-
ogy has changed markedly since the first cases of
chloroquine (CQ)-resistant Plasmodium falciparum
were reported in the 1980s[1,2]. The efficacy of chloro-
quine against P. vivax has not been previously assessed
in Vanuatu. Between 1988 and 2000, the national annual
parasite incidence reported by passive case detection
had decreased from 184 to 34 cases per 1,000 popula-
tion after implementation of widespread insecticide-trea-
ted bed net distribution and new treatment guidelines
[3]. In 1991, malaria treatment policy was changed from
CQ monotherapy to CQ and sulphadoxine/pyrimetha-
mine (SP) for uncomplicated P. falciparum infection.
The regimen for Plasmodium vivax infection was chan-
ged from CQ + primaquine to CQ alone due to reports
that glucose-6-phosphate dehydrogenase (G6PD) defi-
ciency was relatively common in this population[4].
Elsewhere in the Asia-Pacific region, CQ+SP had already
been found to be safe and well-tolerated but with vary-
ing efficacy [5,6]. In the Philippines, the combination
was 87.5% effective compared to 30% for CQ alone[7],
while in Central Java, Indonesia these drugs were 99%
and 70% effective, respectively[8]. Mass treatment of the
inhabitants of another isolated malaria endemic island
in Vanuatu with CQ+SP plus primaquine successfully
eliminated malaria without serious adverse events[9].
Some studies have shown little improvement in CQ+SP
efficacy over SP alone in African and Asian regions with
underlying SP and CQ resistance [10,11]. The efficacy of
chloroquine against vivax malaria in this region has
declined significantly over the last several decades with
resistance rates as high as 22-70% [12-15]. However,
very little is known about anti-malarial drug resistance
in Vanuatu. Genetic mutations associated with resis-
tance to CQ and SP are well known. The mutant pfcrt
76T allele, encoding a lysosomal transmembrane pro-
tein, facilitates the removal of CQ from the parasite
lysosome, where it acts by inhibiting the detoxification
and elimination of haemoglobin digestion products [16].
A combination of multiple point mutations in the dhfr
gene confers resistance to pyrimethamine, a drug target-
ing its enzyme product dihydrofolate reductase [17].
Point mutations in the dhps gene are likewise associated
with resistance to sulphadoxine through inhibition of
parasite dihydropteroate synthase [18]. Point mutations
in these latter two genes have been found in both resis-
tant [19-21] and susceptible P. falciparum populations
and several mutations are, therefore, likely to be
required to confer resistance [22].
As emerging parasite resistance to older anti-malarials
drives the revision of treatment guidelines and the
adoption of newer, more expensive formulations with arte-
misinin derivatives, demonstration of the continued effi-
cacy of CQ+SP through controlled clinical trials supports
policies to conserve scarce healthcare resources [23]. At
the time of this study, the seasonal epidemiology of
malaria in central Vanuatu had not been characterized,
nor had the efficacy of CQ+SP as first-line therapy been
systematically evaluated, in spite of its widespread use over
two decades. Similarly, the presence or absence of known
genetic markers of plasmodial resistance to the current
drug regimen in Vanuatu was unknown. Systematic pol-
icy-driven use of CQ+SP combination therapy may be
changing the epidemiology and resistance patterns of P.
falciparum among Vanuatan islanders. This study was
designed to describe the current malaria situation on Malo
Island in central Vanuatu where cross-sectional prevalence
rates of 20% were observed in 2002 during the same sea-
son [4] by estimating the cross-sectional prevalence of
malaria, the incidence of malaria during the purported
period of high seasonal transmission and the efficacy of
current malaria treatment standards by a 28 day follow-up
in vivo treatment trial and analysing P. falciparum isolates
for molecular markers of anti-malarial resistance.
Methods
Study site
The Republic of Vanuatu is an 80-island archipelago in
the south-western Pacific with a population of approxi-
mately 200,000. Malaria is perennial with seasonal peaks
and troughs, with a peak transmission season lasting
from January to July, associated with hot and wet climate
conditions, and declining transmission from north to
south down the archipelago. The only known malaria
vector is Anopheles farauti sensu stricto, which can breed
in highly saline water [24,25]. Malo is centrally located
(15°38’58"S, 167°05’57” E) within the Sanma Province just
south of the larger island Espirito Santo (Figure 1). It has
a stable population of approximately 4,600 inhabitants
and has been characterized as having hypo- to meso-
endemic malaria. A high season malariometric survey of
1,002 inhabitants in March of 2002 revealed a slide posi-
tive rate of 20% with a P. falciparum to P. vivax ratio of
3:1 and spleen rate (Hackett score 1-2) of 17.5% in chil-
dren two to nine years of age[4]. In this same study, only
8% of P. falciparum infections and 4% of P. vivax infec-
tions were symptomatic on presentation, suggesting ade-
quate transmission to induce semi-immunity.
Study participants
Between February and May 2005, stations were estab-
lished at 45 sites on Malo Island for mass blood screen-
ing of all inhabitants. Slides were stained and examined
within 24 hours unless the participant was symptomatic,
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expedite therapy. Eligible screened participants were
enrolled into either an incidence study or a treatment
trial. Infected individuals deemed ineligible for either
were provided treatment free of charge according to
Ministry of Health guidelines. Informed consent was
obtained from adult participants and from the parents
or legal guardians of minors. All work was performed in
accordance with code 32 of Federal Regulations Part
219 (Protection of Human Subjects), U.S. Department of
Defense, U.S. Navy (SECNAVINST 3900.39C) and
Vanuatu Ministry of Health guidelines for the conduct
of human use research. The protocols and informed
consent processes were reviewed and approved by insti-
tutional review boards prior to initiating research.
Incidence study
Based on previous surveys, approximately 85% of sub-
jects were expected to become parasitaemic during a
16-week follow-up period. Using the sample size for
estimating proportions formula, with an alpha of 0.05
(confidence) and an acceptable lower 95% confidence
limit of 80%, 200 subjects were required to estimate
cumulative incidence of asexual parasitaemia over the
study period. Enrollment was offered to any person > 5
years of age with a negative blood smear on initial
screening, selected into age and gender categories until
closely matching recent Malo Island census data. In all
participants, active surveillance consisted of a weekly
Giemsa blood smear for 13 weeks or until diagnosis of
first plasmodial infection. The first post-screening smear
was performed on day 7 after the initial screening date
and weekly thereafter. Any participant who presented
with fever (> 37.5°F), chills, headache, myalgia, arthral-
gia, or nausea and/or vomiting between scheduled blood
smears was microscopically evaluated for malaria. The
primary endpoint of surveillance for each individual was
their first documented parasitaemia, at which time they
Figure 1 Vanuatu map with location and distribution of participating Malo Island villages for mass blood survey, incidence study and
malaria treatment trial, Feb - May 2005.
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participant contributed person-weeks of follow-up until
one of the following censoring events: 1) malaria parasi-
taemia, 2) voluntary withdrawal, 3) ingestion of anti-
malarials, 4) loss to follow-up, 5) non-malarial illness
prohibiting further participation, or 7) end of study.
Treatment trial
Study procedures closely followed the World Health
Organization (WHO) protocol for the in vivo 28-day
efficacy trial in low to moderate transmission areas for
P. falciparum [26]. Similar methods were followed for P.
vivax as previously performed at the Naval Medical
Research Unit 2 [27]. Inclusion criteria were age ≥ 5
years, single species asexual parasitaemia with P. falci-
parum or P. vivax, parasite density > 400/μl( l o w e rt h a n
WHO criterion of 1,000/μl), not pregnant, no consump-
tion of anti-malarials during the prior week, no severe
or complicated malaria (WHO definition), no other
medical conditions requiring referral to a hospital for
treatment, no ongoing antibiotic therapy or indication
for antibiotic therapy, no history suggestive of hypersen-
sitivity to CQ or SP and willingness to remain in the
area until the completion of the study. Eligible volun-
teers provided a finger prick blood sample for repeat
malaria smear, haemoglobin level and collection on
Whatman No. 1 filter paper (Whatman International,
Maidstone, Kent, UK) for polymerase chain reaction
(PCR) testing. Women of childbearing age provided a
urine sample for human chorionic gonadotropin testing
(TestPack® +Plus™ hCG Urine, Abbott, USA). All treat-
ments were directly observed by study personnel.
Uncomplicated P. falciparum-a n dP. vivax -infected
participants received three daily doses of 10 mg/kg oral
CQ (Resochin™ tablets, P.T. Bayer Indonesia) starting on
the day of screening. Plasmodium falciparum-infected
participants also received SP as one dose of 25 mg sul-
phadoxine + 1.25 mg pyrimethamine/kg body weight
(Fansidar™, 25 mg pyrimethamine/500 mg sulphadoxine,
Hoffman La Roche) at the same time as the first dose of
CQ. If a participant vomited during the first thirty min-
utes after ingestion of medication, repeat dosing was
provided. The second 10 mg/kg CQ dose was provided
24 hours later at the participant’s home or place of
work and the final 10 mg/kg dose 24 hours after the
second dose. A health worker evaluated each participant
at their home or work place and collected blood for
malaria smears on days 0, 1, 2, 3, 7, 11, 14, 18, 21, and
28, and at any time a participant reported to the clinic
with fever or other symptoms suggestive of malaria.
Treatment failures were classified as early or late based
on previously described WHO criteria [26].
Laboratory methods
Thick and thin blood smears were stained with Giemsa
and examined by a certified expert microscopist using
1,000× oil immersion light microscopy. Expert certifica-
tion is determined by annual testing with requirement
for 90% sensitivity and 100% specificity on a four spe-
cies, 25 slide examination. At least 200 ocular fields
were examined before a blood film was considered nega-
tive for Plasmodium sp. The microscopist recorded the
number of asexual and sexual forms per 200 white
blood cells in the thick smear. Parasitaemia was
reported as parasites/μl with a conversion multiple of 40
(assumes a white blood cell count of 8,000/μl) for analy-
sis. Genetic testing by PCR was limited to the treatment
trial. Merozoite surface protein 2 (msp-2)g e n o t y p i n g
was performed to aid in distinguishing P. falciparum
recrudescence from re-infection in the treatment trial
and pfcrt, dhfr and dhps PCR analysis was performed to
identify point mutations associated with anti-malarial
resistance. DNA was extracted from blood blot samples
using previously described methods [28] followed by
nested PCR and gene sequence-specific restriction-endo-
nuclease digestion to detect pfcrt and msp-2 alleles as
previously described [16,29]. Dhfr and dhps alleles were
also characterized as previously described [30,31].
Data analysis
All data were recorded on standardized written case
report forms, double entered into a relational database
in MS Access (Microsoft Inc., Redmond, WA) and ana-
lysed using SPSS software (SPSS Inc, Chicago, IL, USA).
Analysis of mass blood screening data included standard
descriptive statistics and stratified analysis by age and
gender. The attributable fraction of fevers due to parasi-
taemia was also calculated [32]. Incidence rates were
calculated in person-time as cases per person-week and
cases per person-year based on the amount of time each
participant contributed to follow-up. Time contributed
by each individual was derived from the date of the last
available blood smear result prior to withdrawal for any
reason. The efficacy of each treatment arm was calcu-
lated as the percent of participants not requiring alter-
native therapy for recurrent parasitaemia during the 28-
day follow-up. The first of two consecutive days without
fever was considered the day of fever clearance. Treat-
ment outcomes were also analysed by actuarial (life
table) analysis as described elsewhere [33]. 95% confi-
dence intervals for treatment efficacy rates and treat-
ment failure rates were determined using the standard
statistical formula 95% CI = estimator +/- (z(1-a/2) ×
standard error). All statistical tests were two-tailed with
significance set at P < 0.05.
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Mass blood screening
4,060 (88% of island population) adults and children
were screened, of which 235 (6%) were infected with
plasmodia based on Giemsa stained blood slides. Slide
positivity rates by age group were 3% for children under
1 year, 10% for 1 to 5 years, 6% for 6 to 15 years, and
5% for over 15 years. Most cases were detected in the
more heavily populated villages of Avunatari, Nanuku
and Avunamblu (Figure 1). The spleen rate among
1,123 children (age 2-9 years) was 2.2% (95%CI 1.4 -
3.3) and consistent with hypo-endemic malaria. Fever
rates among participants with P. vivax and P. falciparum
were 20% and 23%, respectively. The attributable frac-
tion of fevers due to parasitaemia in this population was
only 5.2% (95% CI 4.2-6.2). The presence of fever in
conjunction with a positive malaria smear correlated
with parasite density in P. falciparum infections (F1,34 =
8.48, p = 0.006), but not in P. vivax infections (F1,77 =
1.89, p = 0.174). The P. falciparum to P. vivax ratio was
1.03 with only a single mixed infection identified and
respective geometric mean parasite densities were 4,571
(95%CI 3111 - 6717) and 441 (95% CI 311 - 624). The
percentage of those with P. falciparum or P. vivax
gametocytaemia was 23% (95%CI 16 - 32) and 11% (95%
CI 6 - 19), respectively. No Plasmodium malariae infec-
tions were found. Asexual stage parasites were found in
10 of the 28 (36%) infections with P. falciparum game-
tocytaemia and 100% of those with P. vivax
gametocytaemia.
Incidence study
Two hundred and three individuals without malaria on
initial screening were followed over 13 weeks for devel-
opment of asexual parasitaemia, for a total of 2,303 per-
son-weeks of follow-up. Sixteen week follow-up could
not be achieved due to exhaustion of funds to sustain
maintenance of personnel on site. Participants included
100 males and 103 females aged 5 to 74 years (mean
22) from the villages of Nandiuti (39%), Avunatari
(36%), Nanuku (22%), Avunamblu (1.5%), Small Nanuku
(1%) and Malo Pass (0.5%). The demographic make-up
of the study group was similar to that of the general
population (51% females, 55% children). Ninety-four
percent of participants completed follow-up; of the 12
individuals who did not complete follow-up, seven were
lost and five declined further participation. Seventeen
(8%) participants developed P. falciparum and 43 (21%)
developed P. vivax parasitaemia during follow-up. Chil-
dren under the age of 15 were more likely to develop
parasitaemia during follow-up than adults (OR = 3.3,
95%CI 1.6 - 7.1), an association that persisted whether
those lost to follow-up were assumed to have been
infected (OR = 2.1, 95%CI 1.1 - 3.9) or uninfected (OR
= 3.7, 95%CI 1.8 - 7.7). The all-ages monthly incidence
of P. falciparum peaked during April then rapidly
declined, while P. vivax incidence rose in March, peaked
in April and remained stable during May 2005 (Figure
2). The respective incidence densities for P. vivax and P.
falciparum were 0.97 (95% CI 0.70 - 1.31) and 0.38
(95% CI 0.22 - 0.62) cases per person-year, with a com-
b i n e di n c i d e n c ed e n s i t yo f1 . 3 6( 9 5 %C I1 . 0 4-1 . 7 5 ) .A
potential bias towards lower risk behaviour by enrolling
only those who tested negative in a mass blood screen-
ing may lend to an underestimation of overall risk, how-
ever inclusion of participants with malaria who would
have received treatment with a long half-life drug (CQ)
on enrollment would have also contributed to an early
underestimation of risk due to CQs prophylactic effect.
The higher incidence observed for P. vivax compared to
P. falciparum likely represents hypnozoite-related
relapses from prior infection since radical cure with pri-
maquine was not administered prior to enrollment in
the incidence study. Only 15% of participants who
developed malaria (47% of P. falciparum infections and
2% of P. vivax infections) had fever at the time of diag-
nosis, and there were no cases of severe malaria during
the follow-up period. Geometric mean parasite densities
were higher for P. falciparum than P. vivax, 1005/μl
(range 362 - 2789) vs. 109/μl (range 75 - 185), but both
densities were lower than observed in the mass blood
survey, most likely due to early diagnosis through active
screening in a population with high rates of asympto-
matic infection.
Treatment trial
Since 1991, when Vanuatu implemented malaria treat-
ment guidelines incorporating combination CQ+SP for
P. falciparum malaria, no well-controlled study had
been conducted to assess the regimen’se f f e c t i v e n e s s .
Some studies have shown that combining CQ+SP may
not enhance effectiveness of treatment over either medi-
cation alone [34-36]. In this study, 33 Malo Island parti-
cipants with P. falciparum infections were treated with
CQ+SP and 21 with P. vivax received CQ alone. Both
drugs were given under direct observation and were
well-tolerated without adversee v e n t s .T h ep a r t i c i p a n t s ’
age and gender distributions were representative of the
general population. However, the target enrollment of
50 participants for each Plasmodium species was not
reached due to a less-than-expected prevalence based on
the 2002 survey, reducing the power of this study to
detect treatment failures. Approximately one third of
participants had documented fever and the majority of
them reported at least one symptom associated with
malaria (Table 1). During 28 days of follow-up, one
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appearance of P. vivax parasitaemia after an initial diag-
nosis of P. falciparum mono-infection. None of those in
the treatment trial were identified with an alternate spe-
cies infection during the follow-up period. The average
number of days of fever and asexual parasitaemia
among P. falciparum infections were 1 and 2.1 days,
respectively, and among P. vivax infection, 0.5 and 1.7
days (Figure 3). Asexual stage parasite clearance times
were short (Figure 3). Only a single case of P. vivax had
persistent parasitaemia past day one of therapy (day two
parasite density 40/μl). Six cases of P. falciparum had
detectable parasitaemia on day two but not beyond and
only one persisted until day 3 at low density (120/μl).
Gametocytaemia was common in P. falciparum infec-
tions throughout the follow-up period, as neither SP nor
CQ are effective gametocidal agents[37] and SP is fre-
quently associated with increasing gametocytaemia fol-
lowing therapy, an observation supported in this study
on days six through 20 (Figure 3) [38]. Although CQ
+SP was an effective treatment for asexual P. falciparum
parasitaemia, this combination has the potential to
increase transmission in the early post-treatment period.
Gametocytaemia was not observed on initial diagnosis
or at any time during the 28-day follow-up for any of
the P. vivax cases.
T h e2 8 - d a yc u r er a t ef o rP. vivax infections treated
with CQ was 100% and that for P. falciparum treated
with CQ+SP was 97%. Based on prior long standing cri-
teria for conducting in vivo treatment trials by Naval
Medical Research Unit 2 in Indonesia where chloro-
quine resistance rates for P. falciparum and P. vivax are
high (8,34), a cut-off of > 400 asexual parasites per
microliter of blood was set as the inclusionary parasite
Figure 2 Cases of malaria by species and month over 13 weeks of follow-up, Malo Island, Vanuatu, Feb-May 2005 (n = 203).
Table 1 Demographic, parasitological and clinical
parameters, malaria treatment trial, Malo Island,
Vanuatu, Feb-May 2005 (n = 54)
Treatment Group
Variable CQ for Pv CQ+SP for Pf
Number of participants 21 33
Male : Female 7:14 18:55
Median age in years (range) 11 (5-53) 12 (5-51)
Mean weight in kg (range) 36.1 (15-80) 38.5 (16-66)
Spleen rate in children age 2-9 years (%) 1/15 (5%) 3/24 (9%)
Haemoglobin < 10 g/dl (%) 0 (0%) 1 (3%)
Temperature > 37.5°C (%) 7 (33%) 13 (39%)
Self-reported signs and symptoms* (%) 14 (67%) 31 (94%)
Geometric mean of parasite density/μl
(range)
877 (499-
1540)
5224 (3242-
8418)
*Fever, rigors, headache, myalgia/arthralgia, nausea/vomiting, abdominal pain,
and/or diarrhoea
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WHO standard of 1,000/μl (26), and may have led to
overestimation of treatment efficacy. The single P. falci-
parum treatment failure occurred on day 28 and was
classified as a late parasitological treatment failure
(LPTF). On the day of recurrence, the participant was
asymptomatic with a low parasite density of 200/μla n d
identical msp-2 genotypes on treatment days 0 and 28,
supporting recrudescence vice re-infection. However,
the allelic homogeneity of the infections sampled and
low mean clone number of msp-1 in other samples from
Vanuatu [39] suggest possible re-infection with the same
strain. Although CQ mono-therapy proved highly effica-
cious against primary P. vivax infection in this study,
without primaquine anti-relapse therapy, an unspecified
portion of infections were expected to relapse later than
the 28 days of follow-up observation period in this
study. Additionally, the relatively small sample size pre-
cludes comparison of efficacy of CQ against P. vivax in
Vanuatu with other regional locations with high rates of
resistance. Larger studies are needed.
All 33 P. falciparum pre-treatment isolates from the
treatment trial carried the Thr-76 pfcrt mutant allele as
well as the double Asn-108 + Arg-59 dhfr mutant alleles
and wild type Ala-16, Asn-51 and Ile-164 dhfr alleles.
None of the isolates had dhps mutant alleles; all had
wild type Ser- 436, Ala-437, Lys-540, Ala-581 and Ala-
613. Although the chloroquine-resistant pfcrt allele was
present in all samples tested, mutant allele combinations
in the dhfr and dhps genes associated with clinical resis-
tance were not seen. Point mutations associated with SP
resistance were present, however, emergence of muta-
tions in Pfdhfr usually precede those in Pfdhps [40].
Lack of Pfdhps mutations or triple Pfdhfr mutations in a
population where SP has not been used extensively as
monotherapy[41] may explain its continued efficacy in
Vanuatu, and SP alone may currently be just as effective
against P. falciparum as CQ+SP in Vanuatu. Pvdhps and
Pvdhfr alleles for 18/21 pre-treatment isolates have been
previously reported with high rates of triple (61% with
S58R/T61M/S117T and 6% F57L/S117T/I173F)Pvdhfr
mutations and a single quadruple (one with S58R/
Figure 3 Time course of fever, asexual parasitaemia, and gametocytaemia after treatment initiation in falciparum and vivax malaria
patients, Malo Island, Vanuatu, Feb-May 2005. P. falciparum, 33 cases; P. vivax, 21 cases
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Pvdhps alleles [22]. This suggests that indiscriminate use
of CQ+SP over the preceding fourteen years has
selected for Pvdhfr resistant alleles. Fortunately, chloro-
quine appears to remain efficacious against P. vivax,a t
least on this island.
Conclusions
This study confirmed that malaria remains hypo- to
meso-endemic on Malo and that P. vivax transmission
is more than twice as likely as that of P. falciparum at
the time of year of the 13-week observation. However,
this ratio likely fluctuates throughout the year due to
varying seasonal related transmission intensity of P. fal-
ciparum in Vanuatu [42]. The prevalence of malaria
infection in 2005, 6%, was significantly less than that
observed three years earlier (20%)[4]. The earlier survey
also semi-quantitatively detected G6PD deficiency in
10% of individuals tested. High gametocyte carrier rates
at the end of the peak transmission season and differ-
ences in fever and infection risk between children and
adults suggest a persistent parasite reservoir throughout
the presumed low transmission season. Gametocidal and
liver stage-active drugs like primaquine may have a role
for malaria control in this relatively isolated, low trans-
mission area. Decisions about the use of primaquine for
its gametocidal activity must be weighed against the nat-
ural background rate and clinical importance of G6PD
deficiency in this population. A closer look at the impact
of local public health measures (e.g., insecticide-treated
bed net distribution and changes in treatment policy)
and location-specific transmission dynamics is warranted
to determine if they may play a more significant role in
malaria transmission intensity than seasonal climatic
patterns. A systematic entomological analysis to deter-
mine blood feeding frequency, times and location pre-
ferences (indoors or outdoors) for An. farauti s.s. and
t h e i rr e l a t i o n s h i pt ob e dn e tu s ew o u l db el o g i c a ln e x t
steps in improving understanding and control of malaria
on Malo Island.
The combination of a cross-sectional mass blood
screening survey, incidence study, and a treatment trial
in a malaria-endemic island population provided the
Vanuatu Ministry of Health with useful epidemiological
and clinical data on malaria prevalence and transmission
trends, as well as seasonal incidence and treatment effi-
cacy fourteen years after a change in treatment guide-
lines in response to emerging CQ resistance.
Additionally, the absence of Pfdhfr and Pfdhps allele
combinations associated with SP resistance and mainte-
nance of the CQ resistance conferring Thr-76 pfcrt
mutant allele after extended use in combination with
CQ was unexpected and potentially indicates a domi-
nance of chloroquine’s selective pressure over that of SP
for P. falciparum in Vanuatu. The opposite appears to
be true for P. vivax in Vanuatu, where the CQ + SP
combination has likely been used to treat P. vivax in
areas where limited diagnostic capabilities preclude con-
firmation of species, like Malo Island. Additional studies
of these observations are warranted. A comprehensive
approach to evaluating the state of malaria in specific
locations like Malo Island as presented here can greatly
assist health care policy decision makers by providing
the information necessary to make data-driven treat-
ment and prevention program adjustments and building
a foundation for future malaria research and
interventions.
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